|

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

RECRUITINGSponsored by Washington University School of Medicine
Actively Recruiting
SponsorWashington University School of Medicine
Started2019-05-29
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04354064

Summary

Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Eligible healthy donors will be at least 18 years of age.

Exclusion Criteria:

* Healthy donors younger than 18 years of age

Conditions14

Breast CancerCancerColon CancerEsophageal CancerGastrointestinal CancerGenitourinary CancerHead and Neck CancerHealthy VolunteerLung CancerMelanoma

Locations1 site

Washington University School of Medicine
St Louis, Missouri, 63110
Melissa Reimers, M.D.314-362-7249cbumb@wustl.edu

Browse More Trials

Cancer trialsBreast Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.